Workflow
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
CTMXCytomX(CTMX) Newsfilter·2024-04-03 12:00
  • Achievement of latest clinical candidate triggers additional 5millionmilestonepaymenttoCytomXandisthethirdmilestoneachievedinthecollaborationtodate−−CytomX−retainsUSco−commercializationandeconomicrightsforselectprograms−SOUTHSANFRANCISCO,Calif.,April03,2024(GLOBENEWSWIRE)−−CytomXTherapeutics,Inc.todayannouncedtheachievementofasecondclinicalcandidatenominationunderthecompanies′TCBcollaborationwithAstellas,triggeringa5 million milestone payment to CytomX and is the third milestone achieved in the collaboration to date - - CytomX-retains US co-commercialization and economic rights for select programs - SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. today announced the achievement of a second clinical candidate nomination under the companies' TCB collaboration with Astellas, triggering a 5 million milestone payment ...